Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.

about

Clozapine as a Model for Antipsychotic Development.Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.

P2860

Q39400094-1046DDBA-49D7-43F2-9766-16CC869FBC82 Q50092339-2B27DFD4-8B4A-4C32-9A80-E2D19E5807BF

P2860

Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.

Item

http://www.wikidata.org/entity/Q38856074

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.

@en

type

Item

label

Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.

@en

prefLabel

Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.

@en

P1476

Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis

@en

P2093

Denise K Lowe

http://www.w3.org/2001/XMLSchema#string

Ericka L Crouse

http://www.w3.org/2001/XMLSchema#string

Kiersten M Pasternak

http://www.w3.org/2001/XMLSchema#string

Travis L Gatesman

http://www.w3.org/2001/XMLSchema#string

P2860

Quetiapine in the treatment of psychosis in Parkinson's disease

The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria.

The clinical symptoms of Parkinson's disease.

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.

The prevalence of Parkinson's disease: a systematic review and meta-analysis.

Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group.

P304

479-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028017693029

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kevin M Bozymski

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28375643

http://www.w3.org/2001/XMLSchema#string

Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.

about

P2860

P2860

Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698